Randomized Trialhigh evidence

Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial.

Circulation·November 8, 2026·PMID 42999953

Why it matters

Progressive kidney disease in heart transplant recipients is driven by calcineurin inhibitor exposure and comorbidities, yet SGLT2 inhibitor evidence in this population is sparse. This trial provides randomized data that dapagliflozin may slow eGFR decline, addressing a key unmet need in post-transplant cardiorenal protection.

Infographic summary of Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled